Abstract
Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. Using the t(4;11) ALL line SEM, we evaluated chemotherapy resistance in NOD.CB17-Prkdcscid/J mice. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with phosphate-buffered saline (PBS), or vincristine (0.5. mg/kg body weight) three times per week for 4. weeks (n=8 per group). The level of P-glycoprotein in SEM cells was increased 3-fold by vincristine treatment compared to PBS-treated mice. Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease. These data describe a novel inducible model for investigating multi-drug resistance mechanisms in high-risk t(4;11) ALL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 49-54 |
| Number of pages | 6 |
| Journal | Cancer Letters |
| Volume | 296 |
| Issue number | 1 |
| DOIs | |
| State | Published - Oct 2010 |
Fingerprint
Keywords
- Leukemia
- Multi-drug resistance
- P-glycoprotein
- Translocation
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). / Zunino, Susan J.; Storms, David H.; Ducore, Jonathan M.
In: Cancer Letters, Vol. 296, No. 1, 10.2010, p. 49-54.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11)
AU - Zunino, Susan J.
AU - Storms, David H.
AU - Ducore, Jonathan M
PY - 2010/10
Y1 - 2010/10
N2 - Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. Using the t(4;11) ALL line SEM, we evaluated chemotherapy resistance in NOD.CB17-Prkdcscid/J mice. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with phosphate-buffered saline (PBS), or vincristine (0.5. mg/kg body weight) three times per week for 4. weeks (n=8 per group). The level of P-glycoprotein in SEM cells was increased 3-fold by vincristine treatment compared to PBS-treated mice. Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease. These data describe a novel inducible model for investigating multi-drug resistance mechanisms in high-risk t(4;11) ALL.
AB - Acute lymphoblastic leukemia (ALL) with translocation t(4;11) is found in 60-85% of infants with ALL and is often refractory to conventional chemotherapeutics after relapse. Using the t(4;11) ALL line SEM, we evaluated chemotherapy resistance in NOD.CB17-Prkdcscid/J mice. SEM cells were injected into the tail vein and engraftment was monitored by flow cytometry. Once engraftment was observed, mice were injected intraperitoneally with phosphate-buffered saline (PBS), or vincristine (0.5. mg/kg body weight) three times per week for 4. weeks (n=8 per group). The level of P-glycoprotein in SEM cells was increased 3-fold by vincristine treatment compared to PBS-treated mice. Survival curves showed that leukemia cell growth was initially delayed by vincristine treatment, but the mice eventually succumbed to disease. These data describe a novel inducible model for investigating multi-drug resistance mechanisms in high-risk t(4;11) ALL.
KW - Leukemia
KW - Multi-drug resistance
KW - P-glycoprotein
KW - Translocation
UR - http://www.scopus.com/inward/record.url?scp=77954762562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954762562&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2010.03.017
DO - 10.1016/j.canlet.2010.03.017
M3 - Article
VL - 296
SP - 49
EP - 54
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
IS - 1
ER -